Company / SG&A Expense
Catalyst Pharmaceuticals Partners, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$193.8M
FY2025
5-year range
$49.6M / $193.8M
FY2021-FY2025
Trend
+9.0%
vs FY2024
Sector context
#72 of 213
Health Care
What the data says
At $194M, Catalyst Pharmaceuticals Partners, Inc.'s sg&a expense ranks #142 of 213 in the Health Care sector. SG&A Expense has increased for 9 consecutive years, from $8M in FY2016 to $194M in FY2025.
Based on SEC 10-K filings.
$194M in FY2025 with a 5-year CAGR of +34.4%.
Increased from $134M to $194M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +50.3%
- 5-Year CAGR
- +34.4%
- 10-Year CAGR
- -
Sector benchmark
#142 of 213 in Health CareTop 66% of 213This company $193.8M Sector average $722.3M
▼
-73.2% below sector average
Key checks
Key Insights
- Catalyst Pharmaceuticals Partners, Inc.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +34.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 9.0% year-over-year.
- Ranks #72 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $193.8M | +9.0% |
| FY2024 | $177.7M | +32.9% |
| FY2023 | $133.7M | +134.2% |
| FY2022 | $57.1M | +15.0% |
| FY2021 | $49.6M | +12.2% |
| FY2020 | $44.2M | +19.9% |
| FY2019 | $36.9M | +132.3% |
| FY2018 | $15.9M | +84.7% |
| FY2017 | $8.6M | +8.7% |
| FY2016 | $7.9M | -8.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026